Stromal Cell–Derived Factor-1 (SDF-1)/CXCL12 Attenuates Diabetes in Mice and Promotes Pancreatic β-Cell Survival by Activation of the Prosurvival Kinase Akt

  1. Tatsuya Yano,
  2. Zhengyu Liu,
  3. Jennifer Donovan,
  4. Melissa K. Thomas and
  5. Joel F. Habener
  1. From the Laboratory of Molecular Endocrinology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts
  1. Address correspondence and reprint requests to Joel F. Habener, MD, Laboratory of Molecular Endocrinology, 55 Fruit St., Thier 306, Massachusetts General Hospital, Boston, MA 02114. E-mail: jhabener{at}partners.org

Abstract

OBJECTIVE—Diabetes is caused by a deficiency of pancreatic β-cells that produce insulin. Approaches to enhance β-cell mass by increasing proliferation and survival are desirable. We determined whether stromal cell–derived factor (SDF)-1/CXCL12 and its receptor, CX chemokine receptor (CXCR)4, are important for the survival of β-cells.

RESEARCH DESIGN AND METHODS—Mouse pancreata and clonal β-cells were examined for expression of SDF-1 and CXCR4, activation of AKT and downstream signaling pathways by SDF-1, and protection against apoptosis and diabetes induced by streptozotocin (STZ).

RESULTS—CXCR4 is expressed in β-cells, and SDF-1 is expressed in microvascular endothelial cells within the islets and in surrounding interstitial stromal tissue. Transgenic mice overexpressing SDF-1 within their β-cells (RIP-SDF-1 mice) are resistant to STZ-induced β-cell apoptosis and diabetes. In MIN6 β-cells, a CXCR4 antagonist (AMD3100) induces apoptosis, increases reactive oxygen species, decreases expression levels of the anti-apoptotic protein Bcl-2, and reduces phosphorylation of the proapoptotic protein Bad. Active phosphorylated prosurvival kinase Akt is increased both in the β-cells of RIP-SDF-1 mice and in INS-1 cells treated with SDF-1 and sensitive to AMD3100. Inhibition of AKT expression by small interfering RNA attenuates the ameliorative effects of SDF-1 on caspase-dependent apoptosis induced by thapsigargin or glucose deprivation in INS-1 β-cells. Specific inhibition of Akt activation by a soluble inhibitor (SH-5) reverses the anti-apoptotic effects of SDF-1 in INS-1 cells and mouse islets.

CONCLUSIONS—SDF-1 promotes pancreatic β-cell survival via activation of Akt, suggesting that SDF-1 agonists may prove beneficial for treatment of diabetes.

Footnotes

  • Published ahead of print at http://diabetes.diabetesjournals.org on 18 September 2007. DOI: 10.2337/db07-0291.

    Additional information for this article can be found in an online appendix at http://dx.doi.org/10.2337/db07-0291.

    The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

    • Accepted September 10, 2007.
    • Received March 13, 2007.
| Table of Contents

This Article

  1. Diabetes vol. 56 no. 12 2946-2957
  1. Online-Only Appendix
  2. All Versions of this Article:
    1. db07-0291v1
    2. 56/12/2946 most recent